Imunon, Inc. Operating Lease Cost
Imunon, Inc. (IMNN) reported Operating Lease Cost of $241.83 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Imunon, Inc. operating lease, cost for the quarter ending 2026-06-30 was $120.92K, a 1.97% increase year-over-year.
- Imunon, Inc. operating lease, cost for the quarter ending 2026-03-31 was $120.92K, a 26.82% decline year-over-year.
- Imunon, Inc. operating lease, cost for the quarter ending 2025-12-31 was $119.07K, a 23.40% decline year-over-year.
- Imunon, Inc. operating lease, cost for the quarter ending 2025-09-30 was $118.57K, a 28.11% decline year-over-year.
- Imunon, Inc. operating lease, cost for fiscal 2025 was $521.46K, a 17.86% decline from fiscal 2024.
- Imunon, Inc. operating lease, cost for fiscal 2024 was $634.85K, a 1.82% decline from fiscal 2023.
- Imunon, Inc. operating lease, cost for fiscal 2023 was $646.63K, a 10.02% increase from fiscal 2022.
- Imunon, Inc. operating lease, cost for fiscal 2022 was $587.74K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $120.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $241.83K 10-Q · filed 2026-08-11 | $360.90K derived: sum of 3 quarters · filed 2026-08-11 | $479.47K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $120.92K 10-Q · filed 2026-05-12 | $239.99K derived: sum of 2 quarters · filed 2026-05-12 | $358.56K derived: sum of 3 quarters · filed 2026-05-12 | $477.14K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $119.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $237.64K derived: sum of 2 quarters · filed 2026-03-31 | $356.23K derived: sum of 3 quarters · filed 2026-08-11 | $521.46K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $118.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $237.15K derived: sum of 2 quarters · filed 2026-08-11 | $402.38K 10-Q · filed 2025-11-13 | $557.83K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $118.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $283.81K 10-Q · filed 2026-08-11 | $439.26K derived: sum of 3 quarters · filed 2026-08-11 | $604.20K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $165.23K 10-Q · filed 2026-05-12 | $320.68K derived: sum of 2 quarters · filed 2026-05-12 | $485.62K derived: sum of 3 quarters · filed 2026-05-12 | $645.57K derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $155.45K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $320.39K derived: sum of 2 quarters · filed 2026-03-31 | $480.33K derived: sum of 3 quarters · filed 2026-03-31 | $634.85K 10-K · filed 2026-03-31 | $652.17K 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $164.94K 10-Q · filed 2024-11-07 | $324.89K derived: sum of 2 quarters · filed 2024-11-07 | $479.40K 10-Q · filed 2025-11-13 | $638.11K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2024-06-30 | $159.94K 10-Q · filed 2024-08-14 | $314.46K 10-Q · filed 2025-08-05 | $473.17K derived: sum of 3 quarters · filed 2025-05-12 | $636.37K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2024-03-31 | $154.51K 10-Q · filed 2025-05-12 | $313.22K derived: sum of 2 quarters · filed 2025-05-12 | $476.43K derived: sum of 3 quarters · filed 2025-05-12 | $641.87K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $158.71K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $321.91K derived: sum of 2 quarters · filed 2025-02-27 | $487.36K derived: sum of 3 quarters · filed 2025-02-27 | $646.63K 10-K · filed 2025-02-27 | ||||
| 2023-09-30 | $163.20K 10-Q · filed 2024-11-07 | $328.65K derived: sum of 2 quarters · filed 2024-11-07 | $487.92K 10-Q · filed 2024-11-07 | $634.86K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $165.45K 10-Q · filed 2024-08-14 | $324.72K 10-Q · filed 2024-08-14 | $471.66K derived: sum of 3 quarters · filed 2024-08-14 | $618.59K derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $159.28K 10-Q · filed 2024-05-13 | $306.21K derived: sum of 2 quarters · filed 2024-05-13 | $453.15K derived: sum of 3 quarters · filed 2024-05-13 | $600.08K derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $146.94K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $293.87K derived: sum of 2 quarters · filed 2024-03-28 | $440.81K derived: sum of 3 quarters · filed 2024-03-28 | $587.74K 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $146.94K 10-Q · filed 2023-11-14 | $293.87K derived: sum of 2 quarters · filed 2023-11-14 | $440.81K 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $146.94K 10-Q · filed 2023-08-10 | $293.87K 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | $146.94K 10-Q · filed 2023-05-11 | |||||||
| 2020-12-31 | $128.43K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $260.30K derived: sum of 2 quarters · filed 2021-03-19 | $391.75K derived: sum of 3 quarters · filed 2021-03-19 | $522.38K 10-K · filed 2021-03-19 | ||||
| 2020-09-30 | $131.86K 10-Q · filed 2020-11-16 | $263.31K derived: sum of 2 quarters · filed 2020-11-16 | $393.95K 10-Q · filed 2020-11-16 | $561.07K derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2020-06-30 | $131.45K 10-Q · filed 2020-08-14 | $262.08K 10-Q · filed 2020-08-14 | $429.21K derived: sum of 3 quarters · filed 2021-03-19 | $559.84K derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2020-03-31 | $130.59K 10-Q · filed 2020-05-15 | $297.76K derived: sum of 2 quarters · filed 2021-03-19 | $428.39K derived: sum of 3 quarters · filed 2021-03-19 | $546.80K derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-12-31 | $167.16K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $297.80K derived: sum of 2 quarters · filed 2021-03-19 | $416.21K derived: sum of 3 quarters · filed 2021-03-19 | $522.38K 10-K · filed 2021-03-19 | ||||
| 2019-09-30 | $130.63K 10-Q · filed 2020-11-16 | $130.59K 10-Q · filed 2019-11-14 | $249.05K derived: sum of 2 quarters · filed 2020-11-16 | $355.22K 10-Q · filed 2020-11-16 | $391.79K 10-Q · filed 2019-11-14 | $495.96K derived: sum of 4 quarters · filed 2020-11-16 | ||
| 2019-06-30 | $118.42K 10-Q · filed 2020-08-14 | $130.59K 10-Q · filed 2019-08-14 | $224.86K 10-Q · filed 2020-08-14 | $261.19K 10-Q · filed 2019-08-14 | $365.33K derived: sum of 3 quarters · filed 2020-08-14 | $474.89K derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $130.59K 10-Q · filed 2020-05-15 | $246.92K derived: sum of 2 quarters · filed 2020-05-15 | $356.47K derived: sum of 3 quarters · filed 2020-05-15 | $466.03K derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $116.32K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $225.88K derived: sum of 2 quarters · filed 2020-03-25 | $335.43K derived: sum of 3 quarters · filed 2020-03-25 | $450.43K 10-K · filed 2020-03-25 | ||||
| 2018-09-30 | $109.55K 10-Q · filed 2019-11-14 | $219.11K derived: sum of 2 quarters · filed 2019-11-14 | $334.11K 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | $109.55K 10-Q · filed 2019-08-14 | $224.55K 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | $115.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |